Literature DB >> 7530692

Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40.

P Björck1, S Braesch-Andersen, S Paulie.   

Abstract

The B-cell surface protein, CD40, belongs to the tumour necrosis factor/nerve growth factor (TNF/NGF) receptor family and plays a crucial role in T cell-dependent B-cell activation. Ligation of this receptor with antibodies or its recently defined ligand, gp39, generates an intracellular signal that, when combined with triggering of surface immunoglobulin or the interleukin-4 (IL-4) receptor, induces a variety of stimulatory effects in B cells. In this study we provide further evidence for the importance of receptor cross-linking in generating this signal and we also report on the presence of a soluble form of CD40. A new CD40 monoclonal antibody (mAb), 17:40, was found to synergize with other CD40 antibodies (mAb89 and S2C6) in inducing proliferation as well as IgE synthesis in IL-4-treated tonsillar B cells. However, both this mAb and mAb89 failed to co-operate with a soluble construct of the CD40 ligand, whereas such co-operation was seen with the S2C6 antibody. Cross-inhibition experiments showed that the 17:40 mAb recognized an epitope that was clearly distinct from that seen by S2C6 and mAb89. Although directed to separate epitopes, both 17:40 and mAb89 completely blocked binding of gp39 to its receptor, while the S2C6 mAb only partially interfered with this binding. The findings suggest a close relationship between the degree of receptor clustering and the strength of the delivered signal. With the access to antibodies recognizing distinct structures on CD40 we also established a sandwich enzyme-linked immunosorbent assay for quantitative determinations of the antigen. With this assay we could demonstrate the presence of a soluble form of CD40 (sCD40) in culture supernatants. The fact that sCD40 also retained its ligand-binding capacity indicates that it may have an important regulatory role and modulate the T cell-dependent stimulation via CD40. Both the finding of soluble receptors and the need for receptor clustering are features that CD40 share with other members of the TNF/NGF receptor family.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530692      PMCID: PMC1415046     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

2.  Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.

Authors:  E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Regulation of expression of the ligand for CD40 on T helper lymphocytes.

Authors:  B E Castle; K Kishimoto; C Stearns; M L Brown; M R Kehry
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

4.  Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence.

Authors:  H Koho; S Paulie; H Ben-Aissa; I Jónsdóttir; Y Hansson; M L Lundblad; P Perlmann
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Inhibition of LFA-1-dependent human B-cell aggregation induced by CD40 antibodies and interleukin-4 leads to decreased IgE synthesis.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

6.  CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.

Authors:  J Kwekkeboom; M De Boer; J M Tager; C De Groot
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

7.  A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors.

Authors:  M C Peitsch; C V Jongeneel
Journal:  Int Immunol       Date:  1993-02       Impact factor: 4.823

8.  CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.

Authors:  R C Allen; R J Armitage; M E Conley; H Rosenblatt; N A Jenkins; N G Copeland; M A Bedell; S Edelhoff; C M Disteche; D K Simoneaux
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

9.  Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM.

Authors:  U Korthäuer; D Graf; H W Mages; F Brière; M Padayachee; S Malcolm; A G Ugazio; L D Notarangelo; R J Levinsky; R A Kroczek
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

10.  The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.

Authors:  A Aruffo; M Farrington; D Hollenbaugh; X Li; A Milatovich; S Nonoyama; J Bajorath; L S Grosmaire; R Stenkamp; M Neubauer
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

View more
  8 in total

1.  CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

2.  Functional activity of CD40 antibodies correlates to the position of binding relative to CD154.

Authors:  T A Barr; A W Heath
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

3.  Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients.

Authors:  R F Schwabe; H Engelmann; S Hess; H Fricke
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

Review 4.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

5.  B cell and monocyte phenotyping: A quick asset to investigate the immune status in patients with IgA nephropathy.

Authors:  Senka Sendic; Ladan Mansouri; Sigrid Lundberg; Anna Nopp; Stefan H Jacobson; Joachim Lundahl
Journal:  PLoS One       Date:  2021-03-19       Impact factor: 3.240

Review 6.  Principles of antibody-mediated TNF receptor activation.

Authors:  H Wajant
Journal:  Cell Death Differ       Date:  2015-08-21       Impact factor: 15.828

7.  Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Authors:  Xiaojie Yu; H T Claude Chan; Christian M Orr; Osman Dadas; Steven G Booth; Lekh N Dahal; Christine A Penfold; Lyn O'Brien; C Ian Mockridge; Ruth R French; Patrick Duriez; Leon R Douglas; Arwen R Pearson; Mark S Cragg; Ivo Tews; Martin J Glennie; Ann L White
Journal:  Cancer Cell       Date:  2018-03-22       Impact factor: 31.743

8.  DNA aptamer-based rolling circle amplification product as a novel immunological adjuvant.

Authors:  Adil S Al-Ogaili; Rohana Liyanage; Jack O Lay; Tieshan Jiang; Christine N Vuong; Shilpi Agrawal; Thallapuranam Krishnaswamy Suresh Kumar; Luc R Berghman; Billy M Hargis; Young Min Kwon
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.